NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 5,714,286 shares of common stock at a public offering price of $3.50 per share. The gross proceeds will be approximately $20.0 million, or $23.0 million if underwriters exercise their 30-day option to purchase an additional 857,142 shares in full. The offering was expected to close on June 4, 2026, subject to customary closing conditions.
The company intends to use net proceeds for working capital and general corporate purposes to support its growth. BTIG, LLC is acting as lead bookrunning manager, with Lucid Capital Markets, LLC as joint bookrunning manager. The offering is made pursuant to an effective shelf registration statement on Form S-3, with a prospectus supplement to be filed with the Securities and Exchange Commission.
Company Focus and Designations
NRx Pharmaceuticals is developing therapeutics based on its NMDA platform for treating central nervous system disorders, specifically suicidal depression, chronic pain and PTSD. The company is developing two primary candidates: NRX-100, preservative-free intravenous ketamine, and NRX-101, oral D-cycloserine/lurasidone. NRX-100 has been awarded Fast Track Designation for the treatment of suicidal ideation in depression, including bipolar depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.
The company has filed an Abbreviated New Drug Application and initiated a New Drug Application filing for NRX-100 for treating suicidal ideation in patients with depression, including bipolar depression. Forward-looking statements regarding the offering’s completion are subject to market conditions and other risks that could materially affect results.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.biospace.com/press-releases/nrx-pharmaceuticals-inc-announces-pricing-of-public-offering-of-common-stock